Marc Guiu

Marc Guiu

Auto-generated profile, based on publicly available information

Marc Guiu

Cancer Science Program, Institute for Research in Biomedicine (IRB Barcelona), The Barcelona Institute of Science and Technology, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
IHIvana Hermanova
Ivana Hermanova
PZPatricia Zúñiga-García
Patricia Zúñiga-García
ACAlfredo Caro-Maldonado
Alfredo Caro-Maldonado
SFSonia Fernandez-Ruiz
Sonia Fernandez-Ruiz
FSFernando Salvador
Fernando Salvador
ACArkaitz Carracedo
Arkaitz Carracedo
Gene dosage is a key defining factor to understand cancer pathogenesis and progression, which requires the development of experimental models that aid better deconstruction of the disease. Here, we model an aggressive form of prostate cancer and show the unconventional association of LKB1 dosage to prostate tumorigenesis. Whereas loss of Lkb1 alone in the murine prostate epithelium was inconsequential for tumorigenesis, its combination with an oncogenic insult, illustrated by Pten heterozygosity, elicited lethal metastatic prostate cancer. Despite the low frequency of LKB1 deletion in patients, this event was significantly enriched in lung metastasis. Modeling the role of LKB1 in cellular systems revealed that the residual activity retained in a reported kinase-dead form, LKB1K78I, was sufficient to hamper tumor aggressiveness and metastatic dissemination. Our data suggest that prostate cells can function normally with low activity of LKB1, whereas its complete absence influences prostate cancer pathogenesis and dissemination.

9 November 2023 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
ALAlicia Llorente
Alicia Llorente
MBMaría Teresa Blasco
María Teresa Blasco
IEIrene Espuny
Irene Espuny
MGMarc Guiu
Marc Guiu
CBCecilia Ballaré
Cecilia Ballaré
RGRoger R. Gomis
Roger R. Gomis
MAF amplification increases the risk of breast cancer (BCa) metastasis through mechanisms that are still poorly understood yet have important clinical implications. Oestrogen-receptor-positive (ER+) BCa requires oestrogen for both growth and metastasis, albeit by ill-known mechanisms. Here we integrate proteomics, transcriptomics, epigenomics, chromatin accessibility and functional assays from human and syngeneic mouse BCa models to show that MAF directly interacts with oestrogen receptor alpha (ERα), thereby promoting a unique chromatin landscape that favours metastatic spread. We identify metastasis-promoting genes that are de novo licensed following oestrogen exposure in a MAF-dependent manner. The histone demethylase KDM1A is key to the epigenomic remodelling that facilitates the expression of the pro-metastatic MAF/oestrogen-driven gene expression program, and loss of KDM1A activity prevents this metastasis. We have thus determined that the molecular basis underlying MAF/oestrogen-mediated metastasis requires genetic, epigenetic and hormone signals from the systemic environment, which influence the ability of BCa cells to metastasize.